Linike Medical Group Ltd
LNMG · OTC
1/31/2025 | 10/31/2024 | 7/31/2024 | 4/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -2.70 | 17.39 | 0.33 |
| FCF Yield | -1.20% | -0.37% | 0.03% | 0.13% |
| EV / EBITDA | 31.46 | 1,541.38 | -2,202.49 | -249.09 |
| Quality | ||||
| ROIC | 4.27% | 0.41% | -0.93% | -1.34% |
| Gross Margin | 95.46% | 99.68% | 99.47% | 100.00% |
| Cash Conversion Ratio | -0.21 | -4.73 | -0.59 | -0.35 |
| Growth | ||||
| Revenue 3-Year CAGR | 55.31% | 2,354,185.65% | 2,260,741.18% | 2,148,690.23% |
| Free Cash Flow Growth | 40.70% | -538.39% | 22.92% | 188.49% |
| Safety | ||||
| Net Debt / EBITDA | 7.08 | 75.90 | -33.31 | -21.51 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.02 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 3,970.60 | 44,230.65 | 10,504.27 | 795.64 |